Carlsmed names chief product and AI officer as it claims CMS reimbursements

CARLSMED, INC. (CARL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Carlsmed ® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026 revenue guidance raised to $74 million to $78 million CARLSBAD, CALIFORNIA, AUGUST 5, 2026 (G

Teck Resources Limited reported a strike at its Highland Valley Copper mine in British Columbia, reducing operations. The impact on production depends on the strike's duration. The company has contingency plans and aims for a fair collective agreement. Teck warned of potential effects on previously issued guidance due to the labor disruption.

Teck Resources Limited reports a strike at its Highland Valley Copper mine, leading to reduced operations. Production impact remains uncertain, depending on the strike's duration, according to the company.

Moderna and Merck's melanoma vaccine trial showed a 42% reduction in tumor recurrence and 38% in distant spread, impressing doctors. However, shares of both companies fell as investors questioned the vaccine's broader potential and commercial success. Analysts raised concerns about costs and competition. The full data will be presented at a medical conference.

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced lung cancer death risk by 58% in a trial. Amgen reports median survival of 21.1 months vs. 12.7 months with Imfinzi alone. Imdelltra sales grew to $288M in Q2 2026, but represents only 2.9% of Amgen's total revenue. Analysts expect Amgen's revenue to grow 4% annually through 2030.

Johnson & Johnson reported positive results for its investigational drug JNJ-6143 in a Phase 1 prostate cancer trial, with 77% of patients showing a confirmed PSA decline. The company selected a 50-mg daily dose for Phase 2 testing. The drug is designed to target the androgen receptor and BRD4 protein. Johnson & Johnson acquired Halda Therapeutics, the drug's original developer, for $3.05 billion in 2025.